AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 8 - (NewsRx.com & NewsRx.net) -- Postmenopausal women with low spinal bone mineral density (BMD) and no previous history of vertebral fracture, who received Actonel (risedronate sodium tablets) 5 mg daily for up to 3 years, were 75% less likely to experience a first vertebral fracture than women in the control group, according to a new analysis.
Published in journal Osteoporosis International, the results confirm the fracture reduction efficacy of Actonel in patients without vertebral fractures.
Vertebral fractures are among the most common osteoporotic fractures. In the U.S., an estimated 700,000 vertebral fractures occur every year. Data show that among postmenopausal women who sustain a vertebral fracture, 1 out of 5 will suffer their next vertebral fracture within just 1 year, potentially leading to a fracture cascade.
"Osteoporosis, long considered a slow developing disease, can actually progress quickly once a fracture occurs. The ability to prevent a first fracture is crucial for clinicians in the fight against osteoporosis. This is extremely important since osteoporosis affects more than 10 million people in the U.S.," said Robert Heaney, MD, of Creighton University in Omaha, Nebraska. "This 75% reduction in the risk of first fracture helps confirm that Actonel is a clinically significant treatment for postmenopausal women with osteoporosis."
The analysis assessed the risk of ...
Source: HighBeam Research, Research: Early intervention with Actonel reduces risk of first...